DeepMed Research

Innovent Biologics (Suzhou) Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Phase 1

Recruiting

Conditions: Solid Tumors or Lymphoma

Interventions: Biological: IBI363

First Posted Date: 2022-07-15

Last Posted Date: 2023-12-29

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 260

Registration Number: NCT05460767

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions: Drug: IBI343

First Posted Date: 2022-07-14

Last Posted Date: 2025-04-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 470

Registration Number: NCT05458219

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Sun Yat-sen Memorial Hospital Sun Yat-Sen university, Guangzhou, Guangzhou, China
🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, China

and more 36 locations

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Phase 2

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Biological: dose 2 IBI302
Biological: dose 1 IBI302
Drug: Aflibercept

First Posted Date: 2022-06-03

Last Posted Date: 2024-06-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 132

Registration Number: NCT05403749

Locations: 🇨🇳
Shanghai First People's Hospital, Shanghai, Shanghai, China

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: Period 2 IBI112 dose 4
Drug: Period 1 IBI112 Placebo
Drug: Period 2 IBI112 dose 3
Drug: Period 1 IBI112 dose 2
Drug: Period 2 IBI112 Placebo
Drug: Period 1 IBI112 dose 1

First Posted Date: 2022-05-17

Last Posted Date: 2024-07-30

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 150

Registration Number: NCT05377580

Locations: 🇨🇳
First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: sintilimab (before the change)
Drug: sintilimab (after the change)

First Posted Date: 2022-04-20

Last Posted Date: 2023-08-21

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 117

Registration Number: NCT05337267

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas

Phase 1

Recruiting

Conditions: Solid Malignancies or Lymphomas

Interventions: Biological: IBI363

First Posted Date: 2022-03-22

Last Posted Date: 2024-12-18

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 84

Registration Number: NCT05290597

Locations: 🇦🇺
Kate.Wilkinson1@health.nsw.gov.au, Sydney, New South Wales, Australia
🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺
Sydney Southwest Private Hospital, Sydney, New South Wales, Australia

and more 1 locations

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2

Not yet recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Sintilimab
Drug: Rituximab

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 100

Registration Number: NCT05280626

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Phase 1

Withdrawn

Conditions: Advanced Malignancies

Interventions: Drug: IBI397
Drug: IBI397+Sintilimab
Drug: IBI397+Rituximab

First Posted Date: 2022-02-18

Last Posted Date: 2023-09-05

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Registration Number: NCT05245916

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

Phase 1

Completed

Conditions: CLDN18.2 Positive Solid Tumors

Interventions: Drug: IBI345

First Posted Date: 2022-01-20

Last Posted Date: 2023-05-24

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 7

Registration Number: NCT05199519

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: IBI321

First Posted Date: 2021-12-29

Last Posted Date: 2021-12-29

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 110

Registration Number: NCT05172856

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy